TY - JOUR
T1 - New Generation Gepants
T2 - Migraine Acute and Preventive Medications
AU - Moreno-Ajona, David
AU - Villar-Martínez, María Dolores
AU - Goadsby, Peter J.
N1 - Funding Information:
Conflicts of Interest: D.M.-A. declares no conflict of interest. M.D.V.M. declares no conflict of interest. P.J.G. reports over the last 36 months, grants and personal fees from Amgen and Eli-Lilly and Company, grant from Celgene, and personal fees from Aeon Biopharma, Alder Biopharmaceu-ticals, Allergan, Autonomic Technologies Inc., Biohaven Pharmaceuticals Inc., Clexio, Electrocore LLC, eNeura, Epalex, Impel Neuropharma, MundiPharma, Novartis, Santara Therapeutics, Teva Pharmaceuticals, Trigemina Inc., WL Gore, and personal fees from MedicoLegal work, Massachusetts Medical Society, Up-to-Date, Oxford University Press, and Wolters Kluwer; and a patent magnetic stimulation for headache assigned to eNeura without fee.
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/3/16
Y1 - 2022/3/16
N2 - Migraine is a debilitating disease whose clinical and social impact is out of debate. Tolera-bility issues, interactions, contraindications, and inefficacy of the available medications make new options necessary. The calcitonin-gene-related peptide (CGRP) pathway has shown its importance in migraine pathophysiology and specific medications targeting this have become available. The first-generation CGRP receptor antagonists or gepants, have undergone clinical trials but their development was stopped because of hepatotoxicity. The new generation of gepants, however, are efficacious, safe, and well tolerated as per recent clinical trials. This led to the FDA-approval of rimegepant, ubrogepant, and atogepant. The clinical trials of the available gepants and some of the newer CGRP-antagonists are reviewed in this article.
AB - Migraine is a debilitating disease whose clinical and social impact is out of debate. Tolera-bility issues, interactions, contraindications, and inefficacy of the available medications make new options necessary. The calcitonin-gene-related peptide (CGRP) pathway has shown its importance in migraine pathophysiology and specific medications targeting this have become available. The first-generation CGRP receptor antagonists or gepants, have undergone clinical trials but their development was stopped because of hepatotoxicity. The new generation of gepants, however, are efficacious, safe, and well tolerated as per recent clinical trials. This led to the FDA-approval of rimegepant, ubrogepant, and atogepant. The clinical trials of the available gepants and some of the newer CGRP-antagonists are reviewed in this article.
KW - Acute medications
KW - CGRP
KW - Gepants
KW - Migraine
KW - Painkillers
UR - http://www.scopus.com/inward/record.url?scp=85126595072&partnerID=8YFLogxK
U2 - 10.3390/jcm11061656
DO - 10.3390/jcm11061656
M3 - Article
AN - SCOPUS:85126595072
SN - 2077-0383
VL - 11
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
IS - 6
M1 - 1656
ER -